Inhibitors develop in about 20–30% of patients with severe hemophilia A (<1% normal FVIII activity) and in about 10% in patients with non-severe hemophilia A (1–40% normal FVIII activity) (23, 24). This evidence concerns the gene F8 and hemophilia A.